184 related articles for article (PubMed ID: 10342361)
21. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism.
Camacho P; Gordon D; Chiefari E; Yong S; DeJong S; Pitale S; Russo D; Filetti S
Thyroid; 2000 Nov; 10(11):1009-12. PubMed ID: 11128715
[TBL] [Abstract][Full Text] [Related]
22. Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma?
Gozu H; Avsar M; Bircan R; Sahin S; Ahiskanali R; Gulluoglu B; Deyneli O; Ones T; Narin Y; Akalin S; Cirakoglu B
Thyroid; 2004 Nov; 14(11):975-80. PubMed ID: 15671779
[TBL] [Abstract][Full Text] [Related]
23. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
24. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R.
Tanaka K; Inoue H; Miki H; Masuda E; Kitaichi M; Komaki K; Uyama T; Monden Y
Br J Cancer; 1997; 76(5):594-9. PubMed ID: 9303357
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
26. Activating TSH-receptor mutation (Met453Thr) as a cause of adenomatous non-autoimmune hyperthyroidism in a 3-year-old boy.
Kraemer S; Rothe K; Pfaeffle R; Fuehrer-Sakel D; Till H; Muensterer OJ
J Pediatr Endocrinol Metab; 2009 Mar; 22(3):269-74. PubMed ID: 19492584
[TBL] [Abstract][Full Text] [Related]
27. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma.
Wasenius VM; Hemmer S; Karjalainen-Lindsberg ML; Nupponen NN; Franssila K; Joensuu H
Am J Surg Pathol; 2005 Apr; 29(4):544-9. PubMed ID: 15767811
[TBL] [Abstract][Full Text] [Related]
28. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
29. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas.
Russo D; Arturi F; Suarez HG; Schlumberger M; Du Villard JA; Crocetti U; Filetti S
J Clin Endocrinol Metab; 1996 Apr; 81(4):1548-51. PubMed ID: 8636365
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutations in an Italian cohort of thyroid cancers.
Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization.
Tanaka K; Inoue H; Miki H; Komaki K; Monden Y
Clin Endocrinol (Oxf); 1996 Mar; 44(3):259-67. PubMed ID: 8729520
[TBL] [Abstract][Full Text] [Related]
32. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
33. Lack of p16/CDKN2 alterations in thyroid carcinomas.
Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
[TBL] [Abstract][Full Text] [Related]
34. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
35. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia PL; Marsh DJ; Zheng Z; Zedenius J; Komminoth P; Frisk T; Wallin G; Parsons R; Longy M; Larsson C; Eng C
Cancer Res; 1997 Nov; 57(21):4710-3. PubMed ID: 9354427
[TBL] [Abstract][Full Text] [Related]
36. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
[TBL] [Abstract][Full Text] [Related]
37. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
Namba H; Nakashima M; Hayashi T; Hayashida N; Maeda S; Rogounovitch TI; Ohtsuru A; Saenko VA; Kanematsu T; Yamashita S
J Clin Endocrinol Metab; 2003 Sep; 88(9):4393-7. PubMed ID: 12970315
[TBL] [Abstract][Full Text] [Related]
38. Telomerase activity in human thyroid carcinomas originating from the follicular cells.
Brousset P; Chaouche N; Leprat F; Branet-Brousset F; Trouette H; Zenou RC; Merlio JP; Delsol G
J Clin Endocrinol Metab; 1997 Dec; 82(12):4214-6. PubMed ID: 9398742
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays.
Zhao J; Leonard C; Brunner E; Gemsenjäger E; Heitz PU; Odermatt B
Int J Oncol; 2006 Nov; 29(5):1041-51. PubMed ID: 17016634
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial DNA alterations in thyroid cancer.
Tong BC; Ha PK; Dhir K; Xing M; Westra WH; Sidransky D; Califano JA
J Surg Oncol; 2003 Mar; 82(3):170-3. PubMed ID: 12619060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
